(1) 基因药物成药性研究
(2) 肿瘤疫苗研发
(3) 大分子药物递送

（1）中国药科大学, 2022年高层次引进人才科研启动经费，2021-10 至 2027-10，100万元，在研，主持
（2）江苏省自然科学基金青年基金项目，“肠淋巴转运-脂肪生态位代谢调节”型口服脂质纳米疫苗在急性髓系白血病中的研究，2022-07-01 至 2025-06-30，20万元，在研，主持

1. Kumar, Virender, Xiaofei Xin, Jingyi Ma, Chalet Tan, Natalia Osna, and Ram I. Mahato. "Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis." Advanced Drug Delivery Reviews (2021): 113888. (IF: 15.47)
2. Xiaofei Xin, Virender Kumar, Feng Lin, Vinod Kumar, Rajan Bhattarai, Vijaya R. Bhatt, Chalet Tan, and Ram I. Mahato. "Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy." Science advances 6, no. 46 (2020): eabd6764. (IF: 14.136)
3. Xiaofei Xin, Feng Lin, Qiyue Wang, Lifang Yin, and Ram I. Mahato. "ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer." ACS applied materials & interfaces 11, no. 16 (2019): 14647-14659. (IF:8.456)
4. Xin, Xiaofei, Xiaoqing Du, Qingqing Xiao, Helena S. Azevedo, Wei He, and Lifang Yin. "Drug nanorod-mediated intracellular delivery of microRNA-101 for self-sensitization via autophagy inhibition." Nano-micro letters 11, no. 1 (2019): 1-16. (IF:9.043)
5. Xiaofei Xin, Chao Teng, Xiaoqing Du, Yaiqi Lv, Qingqing Xiao, Yubing Wu, Wei He, and Lifang Yin. "Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endolysosomal route." Theranostics 8, no. 13 (2018): 3474. (IF:8.537)
6. Qin, Chao#, Xiaofei Xin#, Xue Pei, Lifang Yin, and Wei He. "Amorphous Nanosuspensions Aggregated from Paclitaxel–Hemoglobulin Complexes with Enhanced Cytotoxicity." Pharmaceutics 10, no. 3 (2018): 92. (IF: 4.773)
7. Xiaofei Xin, Xue Pei, Xin Yang, Yaqi Lv, Li Zhang, Wei He, and Lifang Yin. "Rod-shaped active drug particles enable efficient and safe gene delivery." Advanced Science 4, no. 11 (2017): 1700324. (IF:9.034)
8. He, Wei#, Xiaofei Xin#, Yongji Li, Xiaopeng Han, Chao Qin, and Lifang Yin. "Rod‐shaped drug particles for cancer therapy: the importance of particle size and participation of Caveolae pathway." Particle & Particle Systems Characterization 34, no. 6 (2017): 1600371. (IF: 4.384)